NCT06725173 Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.
| NCT ID | NCT06725173 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Washington |
| Condition | Retinoblastoma Bilateral |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-03-16 |
| Primary Completion | 2030-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2026-03-16 with a primary completion date of 2030-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is undertake a detailed phenotypic and genotypic study of patients with ocular and secondary cancers due to mutations in the RB1 gene. Our research sequencing approach will allow advanced insight to for further detailed genotypic understanding of parent-of-origin for valuable insight into the genotype-phenotype relationship of this cancer syndrome.
Eligibility Criteria
Inclusion Criteria: * Patients with molecularly proven retinoblastoma due to RB1 or a typical clinical retinoblastoma phenotype with genetic screening pending. * Able to give consent/parent or guardian able to give consent. Exclusion Criteria: * Patients unable or unwilling to undertake consent or clinical testing. * Patients unwilling to donate a saliva or blood sample in order to establish the genetic cause of their condition.
Contact & Investigator
Debarshi Mustafi, MD PhD
PRINCIPAL INVESTIGATOR
University of Washington
Frequently Asked Questions
Who can join the NCT06725173 clinical trial?
This trial is open to participants of all sexes, studying Retinoblastoma Bilateral. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06725173 currently recruiting?
Yes, NCT06725173 is actively recruiting participants. Contact the research team at debarshi@uw.edu for enrollment information.
Where is the NCT06725173 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT06725173 clinical trial?
NCT06725173 is sponsored by University of Washington. The principal investigator is Debarshi Mustafi, MD PhD at University of Washington. The trial plans to enroll 100 participants.